Randomized trials describing lung inflammation after pleurodesis with talc of varying particle size.
We report two trials describing whether talc pleurodesis with a mean particle size of less than 15 microm ("mixed" talc) produces more lung and systemic inflammation than tetracycline or "graded" talc (most particles < 10 microm were removed). First, 20 patients with malignant effusions received tetracycline or mixed talc. Changes in lung and systemic inflammation from lung clearance scans, oxygen saturations, and C-reactive protein from baseline to 48 hours after pleurodesis were recorded. Lung inflammation (change in isotope clearance, talc -9.26, SD 14.3 vs. tetracycline 4.10, SD 13.8 minutes; difference = -13.4; 95% confidence interval [CI], -26.6 to -0.2; p = 0.05) and systemic inflammation (change in C-reactive protein, talc 198 SD 79.2 vs. tetracycline 74 SD 79.4 microg/L; difference = 124; 95% CI, 50 to 199; p = 0.004) were greater after talc. Second, 48 patients received mixed or graded talc, and gas exchange was assessed from changes in the alveolar-arterial oxygen gradient. Mixed talc worsened gas exchange (oxygen gradient change, mixed 2.17 SD 1.74 kPa, 16.3 13.1 mm Hg vs. graded 0.72 SD 2.46 kPa 5.4 18.5 mm Hg, difference = 1.45; 95% CI, 0.2 to 2.7; p = 0.03) and induced more systemic inflammation than graded talc. We conclude that the routine use of graded talc for pleurodesis would reduce the morbidity of this procedure.
Maskell
Nick A
NA
Oxford Pleural Disease Clinic, Oxford Centre for Respiratory Medicine, Churchill Hospital, Oxford Radcliffe NHS Trust, Oxford OX3 7LJ, UK. nickmaskell@doctors.org.uk
Lee
Y C Gary
YC
Gleeson
Fergus V
FV
Hedley
Emma L
EL
Pengelly
Gerry
G
Davies
Robert J O
RJ
D001784:Blood Gas Analysis; D005334:Fever / Q000139:chemically induced; D006801:Humans; D000860:Hypoxia / Q000139:chemically induced; D008168:Lung / Q000000981:diagnostic imaging; D010100:Oxygen / Q000097:blood; D010313:Partial Pressure; D010316:Particle Size; D010996:Pleural Effusion / Q000628:therapy*; D018700:Pleurodesis / Q000009:adverse effects*; D011014:Pneumonia / Q000097:blood / Q000209:etiology*; D011446:Prospective Studies; D011877:Radionuclide Imaging; D013627:Talc / Q000008:administration & dosage / Q000009:adverse effects*
D013627:Talc; D010100:Oxygen